Odiachi Angela, Abegunde Dele
a Department of Health Policy and Management , University of North Carolina , Chapel Hill , NC , USA.
b Health Economist , Public and global Health practitioner , Ilorin , Nigeria.
AIDS Care. 2016 Aug;28(8):1046-51. doi: 10.1080/09540121.2016.1147018. Epub 2016 Feb 17.
This cross-sectional, facility-based study aimed to determine the prevalence, age, and main agent of disclosure among Nigerian children on antiretroviral therapy. It also sought to elicit barriers to, and facilitators of disclosure; and any association between disclosure and health outcomes. A semi-structured questionnaire was administered to 110 parents/caregivers of children ≥6 years. CD4 count, viral load, opportunistic infections and adherence information were also extracted from medical records for all 110 children. The mean age of the children in the study was 10.15 years (SD = 2.97), with a median (range) of 9.50 (6-18) years. According to parents/caregivers' accounts, 34 (30.9%) children knew that they were living with HIV, while 74 (67.3%) did not know. Mean age at disclosure was 10.47 years (SD = 2.62), with a median (range) of 10.00 (6-17) years. Most children (79.4%) were disclosed at home by their parent(s)/caregiver. The rest were disclosed at the hospital: five were disclosed by a healthcare provider, while two were accidentally disclosed. The most common reasons for disclosure were related to adherence issues - either to help prepare the children to take their medicines or that the child had refused to take his/her medicines (39.4%). This was followed by the child asking a lot of questions related to his/her health, frequent visits to the hospital, or why s/he was taking a lot of medicines even though s/he did not feel ill (27.3%). Most parents/caregivers did not disclose because the child was considered too young (84.0%) or will not be able to keep their HIV status a secret (10.7%). Multivariate logistic regression showed that only child's age was a statistically significant predictor of status disclosure (OR 1.69, p = .002; 95% CI 1.21-2.34). There was no association between disclosure and self-reported adherence (p = .615).
这项基于机构的横断面研究旨在确定接受抗逆转录病毒治疗的尼日利亚儿童中信息披露的患病率、年龄及主要推动者。研究还试图找出信息披露的障碍和促进因素,以及信息披露与健康结果之间的任何关联。对110名6岁及以上儿童的家长/照顾者进行了半结构化问卷调查。还从所有110名儿童的病历中提取了CD4细胞计数、病毒载量、机会性感染及依从性信息。研究中儿童的平均年龄为10.15岁(标准差=2.97),中位数(范围)为9.50(6 - 18)岁。根据家长/照顾者的说法,34名(30.9%)儿童知道自己感染了艾滋病毒,而74名(67.3%)儿童不知道。信息披露时的平均年龄为10.47岁(标准差=2.62),中位数(范围)为10.00(6 - 17)岁。大多数儿童(79.4%)是由其家长/照顾者在家中告知的。其余的是在医院被告知的:5名是由医护人员告知的,2名是意外得知的。信息披露最常见的原因与依从性问题有关——要么是为了帮助孩子准备服药,要么是孩子拒绝服药(39.4%)。其次是孩子问了很多与他/她的健康、频繁就医或为什么即使感觉没病却要吃很多药相关的问题(27.3%)。大多数家长/照顾者不披露是因为孩子被认为太小(84.0%)或无法对自己的艾滋病毒感染状况保密(10.7%)。多因素逻辑回归显示,只有孩子的年龄是信息披露状况的统计学显著预测因素(比值比1.69,p = 0.002;95%置信区间1.21 - 2.34)。信息披露与自我报告的依从性之间没有关联(p = 0.615)。